Aptima® HPV 16 18/45
The next-generation genotype test
HPV types 16, 18 and 45 are associated with up to 94% of HPV-related cervical adenocarcinomas. The Aptima HPV® 16 18/45 genotype assay targets these genotypes, identifying more at-risk women with minimal increase in colposcopy rates.1
HPV Genotypes in Invasive Cervical Cancer2,3
- Is uncommon and only prevalent in 0.4% of women with normal cytology.2
- Is the third most common HPV type in invasive cervical cancer.2,3
- Adenocarcinoma is associated with types 16, 18 and 45.2
Cervical Adenocarcinoma is growing concern
Comparison of incidence in cervical cancer subtypes from 1973 to 2015 show that there has been an encouraging 66% decrease in the average incidence of squamous cell carcinoma. In contrast, adenocarcinoma shows a 35% increase in incidence.4
Histological Subtypes of Cervical Cancer5
Squamous Cell Carcinoma (SCC)
Cytology-negative and HPV-positive co-test results occur in 3.7% of women 30 and older6
Genotyping is recommended for women between the ages of 30-65 with negative Pap but positive HPV test results.7,8 When used in combination with cytology results, our Aptima® HPV Assay and HPV 16 18/45 genotype assay help assess risk and guide patient treatment.
Triage Guidelines for Abnormal HPV Results9
We are here to support you. Have a question or need to talk to a Hologic team member?